This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
An Artificial Intelligence (AI) model integrating multiscale foundation model histopathology representations with molecular and clinical features predicts early and late distant recurrence in TAILORx
Joseph Sparano, et al.. npj Breast Cancer, 2026.
DOI: 10.1038/s41523-026-01022-y
-
Robotically-Assisted Surgical Devices - Premarket Submissions Draft Guidance for Industry and Food and Drug Administration Staff
Food and Drug Administration. 2026.
-
Statement from leading physician organizations on the role of augmented intelligence in healthcare
Weekly News Brief: September 28–October 2, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of September 28–October 2, 2026.
This week’s brief covers a multimodal AI model that beat the 21-gene Recurrence Score at predicting early and late breast cancer recurrence, the FDA issued draft guidance for robotically assisted surgical devices, and physician groups said AI should support, not replace, clinical judgment.
To learn more about IICM+, read "Multimodal AI Model May Improve Prediction of Breast Cancer Recurrence Risk," or see the source report in npj Breast Cancer.
For more information on robotically assisted surgical devices, read "FDA Outlines Premarket Testing Expectations for Robotically Assisted Surgical Devices," or see the draft guidance.
To learn more about the role of AI in health care from physician organizations, read "Leading Medical Societies Push Back on Claims That AI Outperforms Physicians," or see the original statement.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.